15:39:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.

Kalender

2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Prenumeration

2022-08-02 08:30:00

Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior Formulation Specialist Fabrice Rose will assume the new role. The reorganization was implemented on August 1, 2022.

Ziccum AB has appointed Fabrice Rose, until recently its Senior Formulation Specialist, as its new Scientific Director. Fabrice Rose is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years’ plus experience in formulation and drug delivery includes ten year’s lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens.

Strong team focus

The reorganisation, the result of extensive consultation and collaboration, is an integral part of Ziccum’s new sharpened strategic focus, initiated with the arrival of new CEO Ann Gidner in May 2022. It has created new roles and clarified existing ones as the company deepens its project work and targets three key vaccine platforms.

CEO Ann Gidner: “I warmly welcome Fabrice to his new role. This reorganization will help us harness the great competence and commitment we have in-house in the best possible way. With a clear company focus and well-defined roles we can move ahead more efficiently and achieve great results together.”